On 14 April 2004, orphan designation (EU/3/04/197) was granted by the European Commission to LungRx Limited, United Kingdom, for treprostinil sodium (inhalation use) for the treatment of pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension.
The sponsorship was transferred to United Therapeutics Europe Ltd, United Kingdom, in January 2008.
The sponsorship was transferred to Unither Therapeutik GmbH, Germany, in February 2019.
The sponsor's address was updated in July 2021.
EU/3/04/197: Public summary of positive opinion for orphan designation of treprostinil sodium (inhalation use) for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (PDF/101.31 KB)
First published: 23/09/2009
Last updated: 23/09/2009
Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
Unither Therapeutik GmbH
Offenbach Am Main 63071
Tel: +49 69 98535179
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: